Evaxion A/S ADR(EVAX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 8:10 AM ET (Korea 9/11 21:10)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.05 | Insider Own | 19.22% | Shs Outstand | 8.3M | Perf Week | 0.98% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | 62.5% | Insider Trans | - | Shs Float | 6.7M | Perf Month | 1.31% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.01 | Inst Own | 6.08% | Short Float | 0.31% | Perf Quarter | -18.21% |
| Income | -0.01B | P/S | 3.47 | EPS this Y | -100% | Inst Trans | 0.77% | Short Ratio | 0.1 | Perf Half Y | -19.9% |
| Sales | 0.01B | P/B | 2.71 | EPS next 5Y | - | ROA | -41.51% | Short Interest | 0.02M | Perf YTD | -35.01% |
| Book/sh | 1.14 | P/C | 1.85 | EPS past 3/5Y | 70.92% 51.86% | ROE | -110.21% | 52W High | -74.49% ($12.15) | Perf Year | 9.93% |
| Cash/sh | 1.68 | P/FCF | - | Sales past 3/5Y | - | ROIC | -53.95% | 52W Low | 13.97% ($2.72) | Perf 3Y | -90.9% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 82.33% | Gross Margin | - | Volatility(W/M) | 4.61% 7.75% | Perf 5Y | -99.33% |
| Dividend TTM | - | EV/Sales | 2.54 | Sales Y/Y TTM | 134.15% | Oper. Margin | -116.83% | ATR (14) | 0.21 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.06 | EPS Q/Q | 42.42% | Profit Margin | -116.42% | RSI (14) | 48.21 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.06 | Sales Q/Q | -100% | SMA20 | -2.41% ($3.18) | Beta | 0.51 | Target Price | $11.25 |
| Payout | - | Debt/Eq | 0.75 | Earnings | 2026/8/20 | SMA50 | 0.04% ($3.1) | Rel Volume | 0.44 | Prev Close | $3.29 |
| Employees | 46 | LT Debt/Eq | 0.69 | EPS/Sales Surpr. | - | SMA200 | -20.42% ($3.9) | Avg Volume(3M) | 0.20M | Price | $3.1 |
| IPO | 2021/2/5 | Option/Short | No/Yes | Trades | 260 | Volume | 87,136 | Change | -5.78% |
Company
EVAX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧪 Evaxion() is a Denmark-based, Copenhagen-headquartered AI-powered techbio company that designs and develops personalized cancer vaccines and infectious disease vaccines using its "AI-Immunology" platform. Its lead candidate, EVX-01, has shown a high response rate in a Phase 2 clinical trial for advanced melanoma.
Over the past 1 year, on the lower side
74% below its 1-year high.
EVAX has weak earning power
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -100.0% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Generally in line with estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -90.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 6.1%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $26M.
EVAX $26M PER -
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is EVAX?
EVAX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of EVAX?
The market cap of EVAX is approximately $26M, ranking 5,203 within its sector.
What is the 52-week high and low for EVAX?
EVAX has recorded a 52-week high of $12.15 and a low of $2.72.
